MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565163 | Name: UBCS039
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

UBCS039 is the first synthetic Sirt6 activator. UBCS039 ameliorated liver damage, including inflammatory responses and oxidative stress. Further study of mechanisms showed that the upregulation of SIRT6 inhibited the inflammation reaction by suppressing the nuclear factor-κB (NF-κB) pathway in the TAA-induced ALF mice model and lipopolysaccharide-stimulated macrophages. In addition, the upregulation of SIRT6 alleviated oxidative stress damage in hepatocytes by regulating the Nrf2/HO-1 pathway. These findings demonstrate that pharmacologic activator of SIRT6 could be a promising target for ALF.

Chemical Structure

UBCS039
UBCS039
CAS#358721-70-7

Theoretical Analysis

MedKoo Cat#: 565163

Name: UBCS039

CAS#: 358721-70-7

Chemical Formula: C16H13N3

Exact Mass: 247.1109

Molecular Weight: 247.30

Elemental Analysis: C, 77.71; H, 5.30; N, 16.99

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 Ready to Ship
10mg USD 550.00 Ready to ship
100mg USD 2,650.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MC-3154; MC3154; MC 3154; UBCS-039; UBCS039; UBC S039
IUPAC/Chemical Name
4-Pyridin-3-yl-4,5-dihydro-pyrrolo[1,2-a]quinoxaline
InChi Key
BSOBGTYXYGHUTD-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13N3/c1-2-7-14-13(6-1)18-16(12-5-3-9-17-11-12)15-8-4-10-19(14)15/h1-11,16,18H
SMILES Code
N12C(C(C3=CC=CN=C3)NC4=C2C=CC=C4)=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
View CoA: current batch, Lot#A20O07B07
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 247.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Toviwek B, Koonawootrittriron S, Suwanasopee T, Jattawa D, Pongprayoon P. Why Bestatin Prefers Human Carnosinase 2 (CN2) to Human Carnosinase 1 (CN1). J Phys Chem B. 2024 Dec 5;128(48):11876-11884. doi: 10.1021/acs.jpcb.4c05571. Epub 2024 Nov 22. PMID: 39574306; PMCID: PMC11626516. 2: Yu Z, Li Y, Bai L, Zheng Y, Liu X, Zhen Y. The triple combination DBDx alleviates cytokine storm and related lung injury. Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113431. doi: 10.1016/j.intimp.2024.113431. Epub 2024 Oct 25. PMID: 39454409. 3: Deng W, Xiong X, Lu M, Huang S, Luo Y, Wang Y, Ying Y. Curcumin suppresses colorectal tumorigenesis through restoring the gut microbiota and metabolites. BMC Cancer. 2024 Sep 12;24(1):1141. doi: 10.1186/s12885-024-12898-z. PMID: 39267014; PMCID: PMC11395590. 4: Dong S, Yang F, Zhang Y, Teng Y, Tang W, Liu J, Fan H. Effect of X-ray irradiation on renal excretion of bestatin through down-regulating organic anion transporters via the vitamin D receptor in rats. Chem Biol Interact. 2024 Aug 25;399:111123. doi: 10.1016/j.cbi.2024.111123. Epub 2024 Jul 2. PMID: 38964638. 5: Jamdar SN, Yadav P, Kulkarni BS, Sudesh, Kumar A, Makde RD. Crystal structure of a newly identified M61 family aminopeptidase with broad substrate specificity that is solely responsible for recycling acidic amino acids. FEBS J. 2024 Jul;291(14):3211-3232. doi: 10.1111/febs.17133. Epub 2024 Apr 22. PMID: 38646733. 6: Zhou Z, Huayu M, Mu Y, Tang F, Ge RL. Ubenimex combined with Albendazole for the treatment of Echinococcus multilocularis-induced alveolar echinococcosis in mice. Front Vet Sci. 2024 Mar 15;11:1320308. doi: 10.3389/fvets.2024.1320308. PMID: 38585297; PMCID: PMC10995866. 7: Nieradko-Iwanicka B, Piasecki J, Borzęcki A. Treatment with bestatin (the exogenous synthetic inhibitor of metalloproteinases) reduces the activity of metalloproteinase 2 and 12 in the spleen and lung tissues of rats in a model of lipopolysaccharide-induced sepsis. Biomed Pharmacother. 2024 May;174:116480. doi: 10.1016/j.biopha.2024.116480. Epub 2024 Mar 27. PMID: 38547765. 8: Nakamichi S, Kubota K, Matsuyama K, Misumi T, Kozuki T, Sugawara S, Naoki K, Kobayashi N, Shukuya T, Shimokawa T, Ishihara M, Wakui H, Hosomi Y, Tanaka H, Saito H, Hosokawa S, Takiguchi Y, Kasai T, Nokihara H, Morita R, Aono H, Furuya N, Okamoto H. A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab- Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non- Small-Cell Lung Cancer: TORG2241 (UBE-Q). Clin Lung Cancer. 2024 Jan;25(1):85-90. doi: 10.1016/j.cllc.2023.09.006. Epub 2023 Oct 4. PMID: 37981477. 9: Shi Y, Guo Q, Jing F, Shang X, Zhou C, Jing F. Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer. Transl Cancer Res. 2023 Oct 31;12(10):2823-2836. doi: 10.21037/tcr-23-435. Epub 2023 Sep 28. PMID: 37969369; PMCID: PMC10643970. 10: Zhang J, Sun S, Liu J, Zhang L, Guo D, Zhang N, Zhao J, Kong D, Xu T, Wang X, Xu W, Li X, Jiang Y. Discovery of a Novel Ubenimex Derivative as a First-in- Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer. Molecules. 2023 Aug 30;28(17):6343. doi: 10.3390/molecules28176343. PMID: 37687169; PMCID: PMC10489073. 11: Zhang T, Lin Q, Liu Z, Yang H. Effect of laparoscopic complete mesocolic excision combined with immunotherapy and its impact on immune function and tumor markers in elderly patients with colon cancer. Pak J Med Sci. 2023 Sep- Oct;39(5):1473-1477. doi: 10.12669/pjms.39.5.7090. PMID: 37680796; PMCID: PMC10480738. 12: Ariefta NR, Pagmadulam B, Hatano M, Ikeda N, Isshiki K, Matoba K, Igarashi M, Nihei CI, Nishikawa Y. Antiplasmodial Activity Evaluation of a Bestatin- Related Aminopeptidase Inhibitor, Phebestin. Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0160622. doi: 10.1128/aac.01606-22. Epub 2023 Jun 14. PMID: 37314349; PMCID: PMC10353437. 13: Kaminska M, Benedyk-Machaczka M, Adamowicz K, Aliko A, Drzazga K, Słysz K, Bielecka E, Potempa J, Mydel P. Bestatin as a treatment modality in experimental periodontitis. J Periodontol. 2023 Nov;94(11):1338-1350. doi: 10.1002/JPER.22-0614. Epub 2023 Apr 25. PMID: 37021727. 14: Hassan AHE, Mahmoud K, Phan TN, Shaldam MA, Lee CH, Kim YJ, Cho SB, Bayoumi WA, El-Sayed SM, Choi Y, Moon S, No JH, Lee YS. Bestatin analogs-4-quinolinone hybrids as antileishmanial hits: Design, repurposing rational, synthesis, in vitro and in silico studies. Eur J Med Chem. 2023 Mar 15;250:115211. doi: 10.1016/j.ejmech.2023.115211. Epub 2023 Feb 14. PMID: 36827952. 15: Ni J, Shang Y, Wang WD, Wang C, Wang AM, Li GJ, Chen SZ. FASN Inhibitors Enhance Bestatin-Related Tumor Cell Apoptosis Through Upregulating PEPT1. Curr Mol Pharmacol. 2023;16(7):771-786. doi: 10.2174/1874467216666221121121549. PMID: 36411574. 16: Zhou Z, Zhou P, Mu Y, Wang L, Cao Z, Dong S, Bao H, Yang B, Xin M, Li R, Ge RL, Tang F. Therapeutic effect on Alveolar echinococcosis by targeting EM- Leucine aminopeptidase. Front Immunol. 2022 Oct 14;13:1027500. doi: 10.3389/fimmu.2022.1027500. PMID: 36311709; PMCID: PMC9614657. 17: Xiu T, Guo Q, Jing F, Shi Y, Jing F. CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3/FAK/NF-κB pathway in gastric cancer cells. Transl Cancer Res. 2022 Aug;11(8):2487-2500. doi: 10.21037/tcr-22-345. PMID: 36093528; PMCID: PMC9459635. 18: Wang A, Shang Y, Ni J, Wang W, Wang C, Li G, Chen SZ. Thymidine Kinase 1 Mediates the Synergistic Antitumor Activity of Ubenimex and Celecoxib via Regulation of Cell Cycle in Colorectal Cancer. J Pharmacol Exp Ther. 2022 Aug;382(2):188-198. doi: 10.1124/jpet.122.001118. Epub 2022 Jul 22. PMID: 35868865. 19: Vourloumis D, Mavridis I, Athanasoulis A, Temponeras I, Koumantou D, Giastas P, Mpakali A, Magrioti V, Leib J, van Endert P, Stratikos E, Papakyriakou A. Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin. J Med Chem. 2022 Jul 28;65(14):10098-10117. doi: 10.1021/acs.jmedchem.2c00904. Epub 2022 Jul 14. PMID: 35833347. 20: Shao LJ, Wang HJ, Wang JR, Yuan XF, Sha Q. Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor. Pak J Med Sci. 2022 May-Jun;38(5):1243-1249. doi: 10.12669/pjms.38.5.4599. PMID: 35799745; PMCID: PMC9247758.

View History

MS78

MS78